FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

GSK has filed for FDA approval to expand the use of its RSV vaccine, Arexvy, to high-risk adults under 50, with a decision anticipated by H1 2026. This strategic move follows a significant 51% decline in Arexvy's 2024 sales to £590 million, primarily due to stricter U.S. vaccination guidelines and heightened competition from Pfizer and Moderna, who already have approvals for this younger demographic. While GSK's shares have risen 13% year-to-date, outperforming the industry, the company's future competitive standing in the evolving RSV vaccine market, particularly for the under-50 segment, hinges on this approval and subsequent public health guidance.

Analysis

GSK's submission for FDA approval to expand its RSV vaccine, Arexvy, to high-risk adults under 50 is a critical strategic move to regain market momentum, with a decision anticipated in the first half of 2026. This filing follows a significant 51% year-over-year decline in Arexvy's 2024 sales to £590 million, a drop precipitated by narrower U.S. ACIP guidelines that restricted the eligible population. The competitive landscape is challenging, as rivals Pfizer and Moderna have already secured FDA approvals for their respective RSV vaccines in broader adult populations, including the under-50 demographic GSK is now targeting. Pfizer's Abrysvo also holds a distinct advantage with its approval for maternal immunization. While GSK's stock has outperformed the industry with a 13% year-to-date gain, the future of its Arexvy revenue stream is contingent not just on this potential approval, but also on securing favorable public health guidance from bodies like the CDC, which is essential to compete effectively against established incumbents.

Key Decisions for Investors

• Investors should view GSK's regulatory filing as a long-term catalyst, with the H1 2026 FDA decision and subsequent CDC recommendations being the key inflection points for Arexvy's market share recovery against Pfizer and Moderna.
• The 51% sales decline in 2024 highlights the significant commercial risk; even with approval, GSK will be the third entrant in the under-50 market, which could pressure pricing and adoption rates.
• Given the stock's 13% year-to-date outperformance, much of the positive regulatory news may already be priced in, warranting a cautious approach until a clearer path to commercial dominance emerges.
• Closely monitor the competitive dynamics, particularly sales figures and marketing strategies for Pfizer's Abrysvo and Moderna's mResvia, as their performance directly impacts GSK's potential to reclaim its initial market leadership in the RSV space.